Skip to content
OpenCapital
Get started

Ligand Pharmaceuticals LGND Agenus Inc. — Gross carrying value

Similar metrics at other companies

Ametek logo
AMEGross Carrying Amount
$5.13B+9.4%
Carrier Global logo
CARRGross Carrying Amount
$8.61B+3.5%
3M logo
MMMGross Carrying Amount
$2.33B-4.5%
Mondelez International logo
MDLZGross Carrying Amount
$3.46B+3.0%
L3Harris Technologies logo
LHXGross Carrying Amount
$9.35B-5.2%
State Street logo
STTGross Carrying Amount
$4.03B+2.7%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%
Enterprise value$5.4B+95.4%
P/E35.9×—
P/S20.1×+4.6×

Profitability

See full
Gross margin91.9%—
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0×0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's agenus inc. — gross carrying value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's agenus inc. — gross carrying value?
Ligand Pharmaceuticals (LGND) reported agenus inc. — gross carrying value of $40.82M in Q1 2026.
What does agenus inc. — gross carrying value mean?
This represents the total historical cost or initial valuation of royalty-based intangible assets associated with the Agenus Inc. partnership before any valuation adjustments. It serves as a baseline measure of the capital investment or acquired value attributed to the specific drug development programs under this license agreement. Tracking this value helps investors understand the scale of the underlying asset portfolio prior to accounting for impairment or amortization.